Purpose: Mobile banking is the latest and most innovative service offered by Banks. The purpose of the study is to investigate the determinants of service quality of mobile banking services in ICICI. Methodology: This study was conducted by using empirical research and Cluster cum Simple random sampling method has been adopted for a sample size of 100 respondents using mobile banking services in ICICI bank Limited. Findings: 35 percent of the respondents are using the SMS mode of mobile banking services. The dimensions of service quality factors of mobile banking services maintained by ICICI Bank Ltd are Convenience, Responsiveness, Security, Accessibility, Assurance, Knowing the customer and efficiency mobile banking services. The factors that satisfy the customers' level towards mobile banking services offered by ICICI Bank Ltd. are banking activities, banking products and other services. The reasons for using mobile banking services are Convenient services, Time-saving and quick service. Originality/Values: This paper shows that the mobile banking service quality dimensions are an important factor to satisfy the customers. The outcomes of this study enhance the knowledge on the performance of ICICI bank as well as customer satisfaction, which are invaluable to all the bank managers and industry players in improving their services.

No abstract

No abstract

Biological products or biopharmaceuticals are medicinal products derived from living organism systems and manufactured by using modern biotechnology that differ widely from the conventional synthetic drugs. According to some estimates, Russia is poised to be among the top five global pharmaceutical Markets in terms of value in the next couple of years. Due to the impetus shown by the government regarding the evolution of the Russian regulatory framework for pharmaceutical products, this and other market trends suggest that Russia will soon become a powerhouse destination for pharmaceutical manufacturers and contract research organizations. Russian law allows the registration of biological drugs defined as medicinal products containing a biological active substance. A bio­logical active substance is a substance that is produced by or extracted from a biological source and requires physical, chemical and biologi­cal testing, characterization of its quality, along with its production process and control. It does not define a biosimilar, nor it provides a regulatory framework for the biosimilar approval; this implies that a full clinical developmental program, similar to the innovator biologi­cal product, must be completed even for a biosimilar. An applicant must submit a registration dossier to the Ministry of Health (MoH), the regulatory body for drugs evaluation, with its affiliation Federal State Budgetary Institution - Scientific Centre for Expert Evaluation of Medicinal Products (FSBI-SCEMP). The complete dossier in Russian must be submitted to the MoH, and should include administrative doc­uments, description of pharmaceutical properties and data about the manufacturing process, quality control, preclinical studies (pharmaco­logical and toxicological) and clinical studies regarding the biological drug. Russia follows the European Guidelines for biosimilars for data requirements for the registration of a biological drug. Today, Russia stands on the verge of becoming a major force in the global pharmaceutical market. The exact contours of its future are as yet undefined; challenges and opportunities co-exist in equal measure. The Russia of today is not the Russia of yesteryears, and tomorrow’s Russia will take yet a different face again. The objective of this manuscript is to explore the Regulatory pathway for registration of Biosimilars in Russia.